logo
Book a meeting
DeuteRx

Deute Rx

Biotechnology, 300 Brickstone Sq, Andover, Massachusetts, 01810, United States, 1-10 Employees

deuterx.com

  • LinkedIn

phone no Phone Number: 19*********

Who is DEUTERX

Formed in 2012, DeuteRx is a virtual biopharmaceutical company focused on improving racemic drugs for patients. Our team has pioneered the use of Deuterium-Enabled Chiral Switching (DECS)...

Read More

lock icon Get Full Access
map
  • 300 Brickstone Sq, Andover, Massachusetts, 01810, United States Headquarters: 300 Brickstone Sq, Andover, Massachusetts, 01810, United States
  • 2012 Date Founded: 2012
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 8731 | NAICS Code: 541714 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from DEUTERX

email-formate-icon
View Email Formats for DeuteRx
arrow
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

Join Now

crown-icon Free credits every month

Frequently Asked Questions Regarding DeuteRx

Answer: DeuteRx's headquarters are located at 300 Brickstone Sq, Andover, Massachusetts, 01810, United States

Answer: DeuteRx's phone number is 19*********

Answer: DeuteRx's official website is https://deuterx.com

Answer: DeuteRx's revenue is $1 Million to $5 Million

Answer: DeuteRx's SIC: 8731

Answer: DeuteRx's NAICS: 541714

Answer: DeuteRx has 1-10 employees

Answer: DeuteRx is in Biotechnology

Answer: DeuteRx contact info: Phone number: 19********* Website: https://deuterx.com

Answer: Formed in 2012, DeuteRx is a virtual biopharmaceutical company focused on improving racemic drugs for patients. Our team has pioneered the use of Deuterium-Enabled Chiral Switching (DECS) to isolate a single stereoisomer from a mixture of interconverting stereoisomers. DECS is a revolutionary strategy that stabilizes the preferred stereoisomer in existing drugs sold as racemic mixtures to reduce deleterious side-effects and improve efficacy. Numerous drugs are still developed and marketed as racemic mixtures because their stereoisomers chemically interconvert in vivo. The development of the single, preferred stereoisomer from the parent racemic drug, also known as a 'chiral switch,' often leads to drugs with superior therapeutic properties. Replacing the exchangeable hydrogen at the chiral center with deuterium enables stabilization and characterization of the single, preferred stereoisomer with a new composition of matter patent protection and an expedited path to market. We have applied DECS to a wide range of clinical therapies, including deuterium-stabilized S-bupropion, for neurological disorders (NTY-184 at Neuromity in 2021), deuterium-stabilized R-pioglitazone for nonalcoholic steatohepatitis (NASH) (PXL065, acquired by Poxel in 2018) and deuterium-stabilized S-lenalidomide (DRX-053, acquired by Celgene in 2012).

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access